2026 Q2 Portfolio Activity
In 2026 Q2, SILVERARC CAPITAL MANAGEMENT, LLC maintained a portfolio of 98 distinct positions. The most significant new addition was ENLIVEN THERAPEUTICS INC, now representing 2.58% of the total fund value. They heavily accumulated shares in ASCENDIS PHARMA A/S, increasing the position by 65.4%. The fund also reduced its exposure to SPDR SERIES TRUST by 92.8%.
Position History
hover any row below to update
Loading…
Total Positions
98
Quarter
2026 Q2
Top Holding
ASND (5.7%)
Top 10 Concentration
42.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 98
SILVERARC CAPITAL MANAGEMENT, LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 5.72% | 2.91% |
#1
11
Prev: #12
|
7.3 |
—
|
81,576 | 65.4% |
P
S
|
206,234 | $55,006,732 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CELC
CELCUITY INC
|
Healthcare | 5.45% | 4.17% |
#2
3
Prev: #5
|
6.2 |
—
|
143,093 | 40.0% |
P
S
|
500,996 | $52,414,202 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 5.15% | 5.16% |
#3
1
Prev: #4
|
3.6 |
—
|
-33,482 | -2.5% |
P
S
|
1,280,707 | $49,563,361 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 4.98% | 2.76% |
#4
9
Prev: #13
|
3.0 |
—
|
-201,066 | -13.4% |
P
S
|
1,301,979 | $47,912,827 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IMNM
IMMUNOME INC
|
Healthcare | 4.44% | 4.13% |
#5
1
Prev: #6
|
4.3 |
—
|
166,731 | 9.0% |
P
S
|
2,017,009 | $42,740,421 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 3.95% | 5.61% |
#6
3
Prev: #3
|
1.6 |
—
|
-264,746 | -40.4% |
P
S
|
390,000 | $38,017,200 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
RYTM
RHYTHM PHARMACE...
|
Healthcare | 3.59% | 2.72% |
#7
7
Prev: #14
|
1.9 |
—
|
5,461 | 1.8% |
P
S
|
311,461 | $34,581,515 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 3.49% | 0.76% |
#8
27
Prev: #35
|
4.4 |
—
|
201,894 | 133.8% |
P
S
|
352,802 | $33,576,166 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 2.79% | 3.36% |
#9
1
Prev: #10
|
1.1 |
—
|
-893,745 | -44.6% |
P
S
|
1,108,295 | $26,820,739 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 2.76% | 2.12% |
#10
7
Prev: #17
|
3.6 |
—
|
325,403 | 36.6% |
P
S
|
1,214,390 | $26,546,565 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 2.58% | — |
#11
Prev: #—
|
4.5 |
—
|
489,382 | — |
NEW
|
489,382 | $24,836,137 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 2.48% | 1.05% |
#12
14
Prev: #26
|
3.5 |
—
|
204,860 | 49.5% |
P
S
|
619,096 | $23,853,769 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ERAS
ERASCA INC
|
Healthcare | 2.40% | 3.06% |
#13
2
Prev: #11
|
1.0 |
—
|
-588,786 | -31.8% |
P
S
|
1,263,026 | $23,138,636 | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SGMT
SAGIMET BIOSCIE...
|
Healthcare | 2.35% | — |
#14
Prev: #—
|
4.4 |
—
|
2,927,698 | — |
NEW
|
2,927,698 | $22,631,106 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.35% | 3.44% |
#15
6
Prev: #9
|
0.9 |
—
|
-132,937 | -43.9% |
P
S
|
169,593 | $22,599,963 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 2.29% | 2.35% |
#16
1
Prev: #15
|
1.4 |
—
|
-5,873 | -8.2% |
P
S
|
65,679 | $21,988,672 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
KOD
KODIAK SCIENCES...
|
Healthcare | 2.21% | 3.86% |
#17
10
Prev: #7
|
0.9 |
—
|
-445,674 | -44.9% |
P
S
|
546,256 | $21,282,134 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
PUT
ARK ETF TR
|
|
PUT Option | 2.19% | — |
#18
Prev: #—
|
4.4 |
—
|
500,000 | — |
NEW
|
500,000 | $21,030,000 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 1.96% | — |
#19
Prev: #—
|
4.3 |
—
|
400,000 | — |
NEW
|
400,000 | $18,816,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
VCYT
VERACYTE INC
|
Healthcare | 1.94% | 0.59% |
#20
20
Prev: #40
|
3.8 |
—
|
138,301 | 77.0% |
P
S
|
318,001 | $18,676,199 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
CALL
SYNDAX PHARMACE...
|
|
CALL Option | 1.58% | 0.76% |
#21
13
Prev: #34
|
3.6 |
—
|
373,600 | 116.8% |
P
S
|
693,600 | $15,162,096 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
GH
GUARDANT HEALTH...
|
Healthcare | 1.56% | 0.93% |
#22
7
Prev: #29
|
1.1 |
—
|
1,312 | 1.3% |
P
S
|
99,826 | $14,976,895 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CCCC
C4 THERAPEUTICS...
|
Healthcare | 1.47% | 0.51% |
#23
20
Prev: #43
|
3.6 |
—
|
1,120,275 | 58.6% |
P
S
|
3,032,060 | $14,159,720 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ZBIO
ZENAS BIOPHARMA...
|
Healthcare | 1.34% | 2.27% |
#24
8
Prev: #16
|
0.5 |
—
|
-626,146 | -55.1% |
P
S
|
509,789 | $12,938,445 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.31% | 0.62% |
#25
13
Prev: #38
|
3.0 |
—
|
166,968 | 32.7% |
P
S
|
678,095 | $12,646,472 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 1.30% | 1.25% |
#26
3
Prev: #23
|
1.0 |
—
|
-31,165 | -2.6% |
P
S
|
1,177,821 | $12,532,015 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
ALXO
ALX ONCOLOGY HL...
|
Healthcare | 1.24% | — |
#27
Prev: #—
|
4.0 |
—
|
5,744,757 | — |
NEW
|
5,744,757 | $11,891,647 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
MANE
VERADERMICS INC
|
Healthcare | 1.21% | — |
#28
Prev: #—
|
4.0 |
—
|
95,000 | — |
NEW
|
95,000 | $11,679,300 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 1.17% | 1.17% |
#29
5
Prev: #24
|
1.0 |
—
|
-10,938 | -5.5% |
P
S
|
186,821 | $11,276,516 | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
AVLN
AVALYN PHARMACE...
|
Healthcare | 1.13% | — |
#30
Prev: #—
|
4.0 |
—
|
330,487 | — |
NEW
|
330,487 | $10,879,632 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
BIIB
BIOGEN INC
|
Healthcare | 1.08% | 0.95% |
#31
3
Prev: #28
|
0.9 |
—
|
-2,866 | -5.6% |
P
S
|
48,101 | $10,392,702 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 1.07% | — |
#32
Prev: #—
|
3.9 |
—
|
1,946,482 | — |
NEW
|
1,946,482 | $10,296,890 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CERS
CERUS CORP
|
Healthcare | 1.05% | 0.59% |
#33
8
Prev: #41
|
2.4 |
—
|
296,190 | 9.3% |
P
S
|
3,472,737 | $10,140,392 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.96% | — |
#34
Prev: #—
|
3.9 |
—
|
500,402 | — |
NEW
|
500,402 | $9,247,429 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
BNTC
BENITEC BIOPHAR...
|
Healthcare | 0.95% | 0.78% |
#35
2
Prev: #33
|
0.9 |
—
|
-37,899 | -5.3% |
P
S
|
679,826 | $9,096,072 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 0.88% | 0.86% |
#36
6
Prev: #30
|
0.9 |
—
|
19 | 0.0% |
P
S
|
145,000 | $8,428,850 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
WGS
GENEDX HOLDINGS...
|
Healthcare | 0.87% | — |
#37
Prev: #—
|
3.8 |
—
|
122,269 | — |
NEW
|
122,269 | $8,393,767 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.87% | 0.80% |
#38
6
Prev: #32
|
0.8 |
—
|
-75,523 | -5.3% |
P
S
|
1,355,459 | $8,349,627 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 0.87% | 0.23% |
#39
19
Prev: #58
|
3.3 |
—
|
2,101,129 | 210.1% |
P
S
|
3,101,129 | $8,342,037 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ORIC
ORIC PHARMACEUT...
|
Healthcare | 0.83% | 1.42% |
#40
19
Prev: #21
|
0.3 |
—
|
-361,137 | -32.8% |
P
S
|
738,873 | $8,001,995 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
CALL
ORIC PHARMACEUT...
|
|
CALL Option | 0.77% | — |
#41
Prev: #—
|
3.8 |
—
|
682,600 | — |
NEW
|
682,600 | $7,392,558 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
N/A
CALL
MONTE ROSA THER...
|
|
CALL Option | 0.75% | — |
#42
Prev: #—
|
3.8 |
—
|
300,000 | — |
NEW
|
300,000 | $7,260,000 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 0.74% | 0.17% |
#43
17
Prev: #60
|
3.3 |
—
|
203,382 | 67.8% |
P
S
|
503,382 | $7,122,855 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CGEN
COMPUGEN LTD
|
Healthcare | 0.71% | 0.72% |
#44
8
Prev: #36
|
0.8 |
—
|
-131,588 | -4.0% |
P
S
|
3,184,257 | $6,814,310 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SLDB
SOLID BIOSCIENC...
|
Healthcare | 0.69% | — |
#45
Prev: #—
|
3.8 |
—
|
668,450 | — |
NEW
|
668,450 | $6,677,816 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
CALL
ABIVAX SA
|
|
CALL Option | 0.69% | — |
#46
Prev: #—
|
3.8 |
—
|
50,000 | — |
NEW
|
50,000 | $6,663,000 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
IBIO
IBIO INC
|
Healthcare | 0.64% | 0.04% |
#47
23
Prev: #70
|
3.3 |
—
|
3,294,490 | 1457.7% |
P
S
|
3,520,490 | $6,160,858 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 0.63% | 1.28% |
#48
26
Prev: #22
|
0.3 |
—
|
-113,228 | -57.8% |
P
S
|
82,800 | $6,055,992 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 0.62% | 1.66% |
#49
29
Prev: #20
|
0.2 |
—
|
-346,820 | -75.3% |
P
S
|
113,494 | $5,946,518 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 0.55% | 0.96% |
#50
23
Prev: #27
|
0.2 |
—
|
-126,659 | -67.9% |
P
S
|
59,959 | $5,323,160 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 |
Showing 1-50 of 98 holdings